Table of Contents Author Guidelines Submit a Manuscript
International Journal of Surgical Oncology
Volume 2012 (2012), Article ID 613980, 6 pages
http://dx.doi.org/10.1155/2012/613980
Review Article

The Role of Secondary Surgery in Recurrent Ovarian Cancer

Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy

Received 31 March 2012; Accepted 30 May 2012

Academic Editor: Constantine P. Karakousis

Copyright © 2012 D. Lorusso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. P. M. Heintz, F. Odicino, P. Maisonneuve et al., “Carcinoma of the ovary,” International Journal of Gynecology and Obstetrics, vol. 83, no. 1, supplement, pp. 135–166, 2003. View at Google Scholar · View at Scopus
  2. F. Sharp, A. D. Blackett, R. E. Leake, and J. S. Berek, “Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 4–7, 1995, Glasgow, UK,” International Journal of Gynecological Cancer, vol. 5, no. 6, pp. 449–458, 1995. View at Publisher · View at Google Scholar · View at Scopus
  3. J. S. Berek, C. Tropé, and I. Vergote, “Surgery during chemotherapy and at relapse of ovarian cancer,” Annals of Oncology, vol. 10, no. 1, supplement, pp. S3–S7, 1999. View at Google Scholar · View at Scopus
  4. G. J. S. Rustin, M. E. L. Van Der Burg, C. L. Griffin et al., “Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial,” The Lancet, vol. 376, no. 9747, pp. 1155–1163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. E. J. Tanner, D. S. Chi, E. L. Eisenhauer, T. P. Diaz-Montes, A. Santillan, and R. E. Bristow, “Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?” Gynecologic Oncology, vol. 117, no. 2, pp. 336–340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Morris, D. M. Gershenson, and J. T. Wharton, “Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy,” Gynecologic Oncology, vol. 33, no. 1, pp. 1–5, 1989. View at Google Scholar · View at Scopus
  7. F. Janicke, M. Holscher, W. Kuhn et al., “Radical surgical procedure improves survival time in patients with recurrent ovarian cancer,” Cancer, vol. 70, no. 8, pp. 2129–2136, 1992. View at Publisher · View at Google Scholar
  8. R. A. Segna, P. R. Dottino, J. P. Mandeli, K. Konsker, and C. J. Cohen, “Secondary cytoreduction for ovarian cancer following cisplatin therapy,” Journal of Clinical Oncology, vol. 11, no. 3, pp. 434–439, 1993. View at Google Scholar · View at Scopus
  9. S. Pecorelli, E. Sartori, and A. Santin, “Follow-up after primary therapy: management of the symptomatic patient- surgery,” Gynecologic Oncology, vol. 55, no. 3, pp. S138–S142, 1994. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Vaccarello, S. C. Rubin, V. Vlamis et al., “Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response,” Gynecologic Oncology, vol. 57, no. 1, pp. 61–65, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Cormio, G. Di Vagno, A. Cazzolla et al., “Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 86, no. 2, pp. 185–188, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Gadducci, P. Iacconi, S. Cosio, A. Fanucchi, R. Cristofani, and A. Riccardo Genazzani, “Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer,” Gynecologic Oncology, vol. 79, no. 3, pp. 344–349, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. S. M. Eisenkop, R. L. Friedman, and N. M. Spirtos, “The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma,” Cancer, vol. 88, pp. 144–153, 2000. View at Google Scholar
  14. A. Munkarah, C. Levenback, J. K. Wolf et al., “Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer,” Gynecologic Oncology, vol. 81, no. 2, pp. 237–241, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. E. H. Tay, P. T. Grant, V. Gebski, and N. F. Hacker, “Secondary cytoreductive surgery for recurrent epithelial ovarian cancer,” Obstetrics and Gynecology, vol. 99, no. 6, pp. 1008–1013, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Y. Zang, Z. T. Li, J. Tang et al., “Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?” Cancer, vol. 100, no. 6, pp. 1152–1161, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Onda, H. Yoshikawa, T. Yasugi, M. Yamada, K. Matsumoto, and Y. Taketani, “Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection,” British Journal of Cancer, vol. 92, no. 6, pp. 1026–1032, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Güngör, F. Ortaç, M. Arvas, D. Kösebay, M. Sönmezer, and K. Köse, “The role of secondary cytoreductive surgery for recurrent ovarian cancer,” Gynecologic Oncology, vol. 97, no. 1, pp. 74–79, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Pfisterer, P. Harter, U. Canzler et al., “The role of surgery in recurrent ovarian cancer,” International Journal of Gynecological Cancer, vol. 15, no. 6, supplement 3, pp. 195–198, 2005. View at Publisher · View at Google Scholar
  20. A. Ayhan, M. Gultekin, C. Taskiran et al., “The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience,” American Journal of Obstetrics and Gynecology, vol. 194, no. 1, pp. 49–56, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J. S. Berek, N. F. Hacker, and L. D. Lagasse, “Survival of patients following secondary cytoreductive surgery in ovarian cancer,” Obstetrics and Gynecology, vol. 61, no. 2, pp. 189–193, 1983. View at Google Scholar · View at Scopus
  22. G. Michel, D. Zarca, D. Castaigne, and M. Prade, “Secondary cytoreductive surgery in ovarian cancer,” European Journal of Surgical Oncology, vol. 15, no. 3, pp. 201–204, 1989. View at Google Scholar · View at Scopus
  23. J. H. Goldie and A. J. Coldman, “A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate,” Cancer Treatment Reports, vol. 63, no. 11-12, pp. 1727–1733, 1979. View at Google Scholar · View at Scopus
  24. P. Harter, A. D. Bois, M. Hahmann et al., “Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial,” Annals of Surgical Oncology, vol. 13, no. 12, pp. 1702–1710, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Harter, J. Sehouli, A. Reuss et al., “Predictive factors for resection in recurrent ovarian cancer. Intergroup of AGO Kommission Ovar, Ago-OVAR, AGO Austria, MITO and NOGGO,” in Proceedings of the 12th Biennal Meeting International Gynecologic Cancer Society, abstract 38, Bangkok, Thailand, October 2008.
  26. S. M. Lenhard, A. Burges, T. R. C. Johnson et al., “Predictive value of PET-CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 140, no. 2, pp. 263–268, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Benedetti Panici, A. De Vivo, F. Bellati et al., “Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer,” Annals of Surgical Oncology, vol. 14, no. 3, pp. 1136–1142, 2007. View at Google Scholar · View at Scopus
  28. P. Harter, M. Hahmann, H. J. Lueck et al., “Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP i trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis,” Annals of Surgical Oncology, vol. 16, no. 5, pp. 1324–1330, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. K. Parmar, J. A. Ledermann, and N. Colombo, “Paclitaxel plus platinum- based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial,” The Lancet, vol. 361, pp. 2099–2106, 2003. View at Google Scholar
  30. J. Pfisterer, M. Plante, I. Vergote et al., “Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4699–4707, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Marth, J. Alexandre, L. C. Hancker et al., “Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum sensitive ovarian cancer (OC) patients (pts): treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial,” Journal of Clinical Oncology, vol. 29, supplement, abstr 5052, 2011. View at Google Scholar
  32. P. Harter and A. Du Bois, “The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence,” Current Opinion in Oncology, vol. 17, no. 5, pp. 505–514, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. R. E. Bristow, I. Puri, and D. S. Chi, “Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis,” Gynecologic Oncology, vol. 112, no. 1, pp. 265–274, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Galaal, R. Naik, R. E. Bristow, A. Patel, A. Bryant, and H. O. Dickinson, “Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer,” Cochrane Database of Systematic Reviews, vol. 6, Article ID CD007822, 2010. View at Google Scholar · View at Scopus
  35. L. Wenzel, H. Q. Huang, B. J. Monk, P. G. Rose, D. Cella, and D. Mackey, “Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5605–5612, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. T. D. Yan, L. Welch, D. Black, and P. H. Sugarbaker, “A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma,” Annals of Oncology, vol. 18, no. 5, pp. 827–834, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. T. D. Yan, D. Black, R. Savady, and P. H. Sugarbaker, “A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei,” Annals of Surgical Oncology, vol. 14, no. 2, pp. 484–492, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. T. D. Yan, D. Black, R. Savady, and P. H. Sugarbaker, “Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma,” Journal of Clinical Oncology, vol. 24, no. 24, pp. 4011–4019, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. T. C. Chua, T. D. Yan, A. Saxena, and D. L. Morris, “Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality,” Annals of Surgery, vol. 249, no. 6, pp. 900–907, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. V. J. Verwaal, S. Van Ruth, E. De Bree et al., “Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer,” Journal of Clinical Oncology, vol. 21, no. 20, pp. 3737–3743, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Pomel, G. Ferron, G. Lorimier et al., “Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study,” European Journal of Surgical Oncology, vol. 36, no. 6, pp. 589–593, 2010. View at Publisher · View at Google Scholar · View at Scopus